{"url":"https://lda.senate.gov/api/v1/filings/db5cee39-fa0f-43dd-99ae-129f50ae3acf/","filing_uuid":"db5cee39-fa0f-43dd-99ae-129f50ae3acf","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2020,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/db5cee39-fa0f-43dd-99ae-129f50ae3acf/print/","filing_document_content_type":"text/html","income":"105000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Nicolas Muzin","dt_posted":"2021-01-19T09:44:19.400000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 Stonington Road","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Silver Spring","registrant_state":"MD","registrant_zip":"20902","registrant":{"id":401105189,"url":"https://lda.senate.gov/api/v1/registrants/401105189/","house_registrant_id":null,"name":"STONINGTON GLOBAL","description":"Government affairs consulting","address_1":"800 Stonington Road","address_2":null,"address_3":null,"address_4":null,"city":"Silver Spring","state":"MD","state_display":"Maryland","zip":"20902","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NICK MUZIN","contact_telephone":"+1 202-858-1100","dt_updated":"2026-06-26T13:11:53.766576-04:00"},"client":{"id":206098,"url":"https://lda.senate.gov/api/v1/clients/206098/","client_id":63,"name":"NOSTRUM PHARMACEUTICALS LLC","general_description":"Pharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-06-02"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicaid reimbursement rates for Oral Nitrofurantoin and other issues affecting generic pharmaceutical manufacturers","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72304,"prefix":null,"prefix_display":null,"first_name":"NICOLAS","nickname":null,"middle_name":"DAVID","last_name":"MUZIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}